NOVN.CH

120.04

+0.45%↑

NOVN.CH

120.04

+0.45%↑

NOVN.CH

120.04

+0.45%↑

NOVN.CH

120.04

+0.45%↑

NOVN.CH

120.04

+0.45%↑

Kodu・Aktsiate loetelu・Lonza Group AG
Search

Lonza Group AG

Avatud

SektorTervishoid

496.2 0.51

Tugev "osta" hinnang

Hinna uuendus 26. mai 2026, 07:01 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

492.7

Max

493.9

Põhinäitajad

By Trading Economics

Sissetulek

57M

483M

Müük

-621M

3B

P/E

Sektori keskmine

35.968

49.701

Dividenditootlus

1.07

Kasumimarginaal

16.345

Töötajad

20,000

EBITDA

-181M

822M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+37.24% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.07%

2.39%

Järgmine tulemuste avaldamine

22. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

-6B

33B

Eelmine avamishind

495.69

Eelmine sulgemishind

496.2

Uudiste sentiment

By Acuity

14%

86%

17 / 345 Pingereas Healthcare

Lonza Group AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. märts 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

DJ

Loe

28. jaan 2026, 06:15 UTC

Tulu

Lonza Sales Grow on New Contract Momentum

DJ

Loe

23. juuli 2025, 08:30 UTC

Tulu
Suurimad hinnamuutused turgudel

Lonza Shares Rise After Outlook Lift for Core Business

DJ

Loe

15. mai 2026, 10:45 UTC

Market Talk

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

DJ

Loe

8. mai 2026, 13:44 UTC

Market Talk
Tulu

Lonza Update Should Reassure on Outlook -- Market Talk

DJ

Loe

9. märts 2026, 10:34 UTC

Market Talk

Lonza Might Disappoint Investors With Capsule Business Valuation -- Market Talk

DJ

Loe

6. märts 2026, 17:12 UTC

Omandamised, ülevõtmised, äriostud

Correct: Lonza to Sell Capsules & Health Ingredients Business to Lone Star Funds

DJ

Loe

6. märts 2026, 17:10 UTC

Omandamised, ülevõtmised, äriostud

Lonza: Total Undiscounted Proceeds Expected to Be at or Above CHF3B

DJ

Loe

6. märts 2026, 17:09 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Retain 40% Stake in CHI

DJ

Loe

6. märts 2026, 17:08 UTC

Omandamised, ülevõtmised, äriostud

Lonza Will Receive Upfront Proceeds of CHF1.7B

DJ

Loe

6. märts 2026, 17:07 UTC

Omandamised, ülevõtmised, äriostud

Lonza: Transaction Expected to Close in 2H

DJ

Loe

6. märts 2026, 17:07 UTC

Omandamised, ülevõtmised, äriostud

Lonza: This Is for Enterprise Value of CHF2.3B at Closing

DJ

Loe

6. märts 2026, 17:06 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Sell Capsules & Health Ingredients Business Lone Star Funds

DJ

Loe

28. jaan 2026, 12:04 UTC

Market Talk
Tulu

Lonza Results Show a Company in Good Shape -- Market Talk

DJ

Loe

28. jaan 2026, 05:35 UTC

Tulu

Lonza Anticipates 2026 Core EBITDA Margin to Reach Level Above 32%

DJ

Loe

28. jaan 2026, 05:34 UTC

Tulu

Lonza Anticipates 2026 Sales Growth of 11-12% at CER

DJ

Loe

28. jaan 2026, 05:33 UTC

Tulu

Lonza Issues 2026 View

DJ

Loe

28. jaan 2026, 05:32 UTC

Tulu

Lonza 2025 Core Ebitda Margin 31.6%

DJ

Loe

28. jaan 2026, 05:32 UTC

Tulu

Analysts Saw Lonza 2025 Core Ebitda at CHF2.27B

DJ

Loe

28. jaan 2026, 05:32 UTC

Tulu

Lonza 2025 Core Ebitda CHF2.06B

DJ

Loe

28. jaan 2026, 05:30 UTC

Tulu

Analysts Saw Lonza 2025 Sales at CHF7.54B

DJ

Loe

28. jaan 2026, 05:30 UTC

Tulu

Lonza 2025 Sales CHF6.53B

DJ

Loe

27. okt 2025, 08:24 UTC

Market Talk

Lonza on Track to Meet Long-Term Goals -- Market Talk

DJ

Loe

23. okt 2025, 10:53 UTC

Market Talk
Tulu

Lonza Set to Recover as Contracts Flow in -- Market Talk

DJ

Loe

23. juuli 2025, 08:00 UTC

Market Talk
Tulu

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

DJ

Loe

23. juuli 2025, 04:44 UTC

Tulu

Lonza 1H Sales Grew 19% at Constant Currency

DJ

Loe

23. juuli 2025, 04:43 UTC

Tulu

Lonza 1H Core Ebitda Margin 29.6%

DJ

Loe

23. juuli 2025, 04:43 UTC

Tulu

Lonza: Margins Will Be Only Minimally Affected

DJ

Loe

23. juuli 2025, 04:42 UTC

Tulu

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

DJ

Loe

23. juuli 2025, 04:42 UTC

Tulu

Lonza: This Is Mainly From Weakening of U.S. Dollar

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Lonza Group AG Prognoos

Hinnasiht

By TipRanks

37.24% tõus

12 kuu keskmine prognoos

Keskmine 676.33 CHF  37.24%

Kõrge 762 CHF

Madal 630 CHF

Põhineb 6 Wall Streeti analüütiku instrumendi Lonza Group AG 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Põhineb 6 analüütiku instrumendi Lonza Group AG aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

17 / 345 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Muud aktsiad sektorist

NOVN.CH

Novartis AG

120.04

↑ +0.45%
help-icon Live chat